Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 7 years, with Q3 2025 value amounting to $3.2 million.

  • Gyre Therapeutics' Other Non-Current Liabilities fell 7004.27% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 7004.27%. This contributed to the annual value of $10.6 million for FY2024, which is 3946.0% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Other Non-Current Liabilities is $3.2 million, which was down 7004.27% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Other Non-Current Liabilities ranged from a high of $17.6 million in Q4 2023 and a low of $55000.0 during Q4 2022
  • Its 4-year average for Other Non-Current Liabilities is $7.6 million, with a median of $7.1 million in 2023.
  • As far as peak fluctuations go, Gyre Therapeutics' Other Non-Current Liabilities soared by 3182181.82% in 2023, and later crashed by 7439.03% in 2025.
  • Over the past 4 years, Gyre Therapeutics' Other Non-Current Liabilities (Quarter) stood at $55000.0 in 2022, then soared by 31821.82% to $17.6 million in 2023, then tumbled by 39.46% to $10.6 million in 2024, then plummeted by 69.67% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.2 million for Q2 2025, and $3.4 million during Q1 2025.